Navigation Links
Large lung cancer study shows potential for more targeted therapies
Date:9/9/2012

A nationwide consortium of scientists has reported the first comprehensive genetic analysis of squamous cell carcinoma of the lung, a common type of lung cancer responsible for about 400,000 deaths each year.

"We found that almost 75 percent of the patients' cancers have mutations that can be targeted with existing drugs -- drugs that are available commercially or for clinical trials," says one of the lead investigators, Ramaswamy Govindan, MD, an oncologist at Washington University School of Medicine in St. Louis and co-chair of the lung cancer group of The Cancer Genome Atlas.

The research appears online Sept. 9 in Nature.

The Cancer Genome Atlas project combines efforts of the nation's leading genetic sequencing centers, including The Genome Institute at Washington University, to describe the genetics of common tumors with the goal of improving prevention, detection and treatment. The Cancer Genome Atlas is supported by the National Cancer Institute and the National Human Genome Research Institute, both parts of the National Institutes of Health (NIH).

The other lung cancer co-chairs are the study's senior author Matthew Meyerson, MD, PhD, of the Broad Institute of Massachusetts Institute of Technology and Harvard University, and Stephen Baylin, MD, of Johns Hopkins University.

The study examined the tumors and normal tissue of 178 patients with lung squamous cell carcinoma. The investigators found recurring mutations common to many patients in 18 genes. And almost all of the tumors showed mutations in a gene called TP53, known for its role in repairing damaged DNA.

Interestingly, the researchers noted that lung squamous cell carcinoma shares many mutations with head and neck squamous cell carcinomas, supporting the emerging body of evidence that cancers may be more appropriately classified by their genetics rather than the primary organ they affect.

"We clearly see mutations in lung cancer that we see in other human cancers," says Richard K. Wilson, PhD, director of The Genome Institute at Washington University. "This reinforces something that we've been seeing in a lot of our cancer genomics work. It's really less about what type of tissue the tumor arises in lung, breast, skin, prostate and more about what genes and pathways are affected."

Current treatment for squamous cell lung cancers includes chemotherapy and radiation, but there are no drugs specifically designed to target this particular type of lung cancer. Squamous cell lung cancer is linked to smoking and responsible for 30 percent of all lung cancer cases.

"With this analysis, we are just starting to understand the molecular biology of lung squamous cell carcinoma," says Govindan, who treats patients at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University. "And now we have identified potential targets for therapies to study in future clinical trials."


'/>"/>

Contact: Julia Evangelou Strait
straitj@wustl.edu
314-286-0141
Washington University School of Medicine
Source:Eurekalert

Related medicine news :

1. Worlds largest meeting of ear, nose, and throat doctors
2. Fruit flies on methamphetamine die largely as a result of anorexia
3. Men with large waists face an increased risk of frequent urination
4. Obesity in type 2 diabetes: Recommendations from guidelines are largely consistent
5. Human papillomavirus types do not replace others after large-scale vaccination
6. Largest review of management and treatment of Barretts dysplasia and adenocarcinoma
7. HIV suppression not as good as previously thought, largest study of viral-load blood tests show
8. Large Breasts Can Take Mental, Physical Toll on Teens
9. Could a larger waistline be a result of too much TV as a child?
10. Obesity, larger waist size associated with better outcomes in heart failure patients
11. OnPage Provides Secure, Rapid Response at New England’s Largest Catholic Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... Ohio (PRWEB) , ... March 28, 2017 , ... Columbus ... was selected as one of few medical professionals in the country to sit on ... Founder of Juvly Aesthetics, in just 2 years Dr. Harper helped propel the clinic ...
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant bariatric surgeon and well-known ... to offer the recently FDA-approved Obalon Balloon System to his patients. The Obalon ... Surgical’s already comprehensive list of weight-loss services. Dr. Liu is proud to ...
(Date:3/28/2017)... ... March 28, 2017 , ... With expansion and efficiency in ... early March. , The seed processing plant opened in Marshallville in 2006, and a ... new office allows opportunity for transition of Patten Seed operations to the Middle Georgia ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Thank you to ... on February 8-10. , This event was exclusive to providers and offered an ... The meeting took place at the Manchester Grand Hyatt where attendees gathered for a ...
(Date:3/28/2017)... ... ... and fungi are probably not the first ingredients that come to mind when thinking about ... your diet can actually improve health outcomes. And the good news is they may be ... new peer-reviewed paper led by Maria Marco, Ph.D. , University of California, ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... NEW YORK , March 27, 2017 FinancialBuzz.com ... According to a ... North America , grew 34 percent to $6.7 billion ... growth rate of (CAGR) over the next five years, from $6.7 billion ... portion of Americans that will be able to purchase cannabis without a ...
(Date:3/27/2017)... 2017 The staggering cost of cancer treatment ... access to the latest treatment options against cancer. Even ... patients have inadequate or no health insurance and are ... Access to modern cancer treatment is almost non-existent for ... The mission statements of pharmaceutical and biotech companies ...
(Date:3/27/2017)... NASHUA, N.H. , March 27, 2017 /PRNewswire/ ... image analysis, workflow solutions and radiation therapy for ... announced that PowerLook® Tomo Detection received Premarket Approval ... (FDA). PowerLook Tomo Detection is a first-of-its-kind, concurrent-read ... tomosynthesis and is the latest innovation available on ...
Breaking Medicine Technology: